NKGen Biotech, Inc., a biotechnology company in the clinical trial phase, was established in 2017 and has its headquarters in Santa Ana, California. This company is dedicated to creating and marketing cutting-edge cell therapies, specifically those derived from activated natural killer (NK) cells, to address both neurodegenerative and cancer-related illnesses within the United States.

Its product pipeline features SNK01, an autologous NK cell therapy candidate currently undergoing Phase I/IIa clinical evaluation for neurological disorders such as Alzheimer's and Parkinson's disease.

Additionally, the company is advancing SNK02, which comprises two distinct therapies: an allogeneic NK cell therapy that has successfully concluded Phase 1 trials, and a HER2-CAR NK cell therapy candidate that remains in preclinical development, both targeting challenging solid tumors. NKGen Biotech has formed a strategic alliance with HekaBio K.K., a Japanese healthcare platform. This partnership aims to cover the entire process – from development and clinical studies to securing regulatory approvals, manufacturing, and commercializing NKGen's autologous NK cell therapies for central nervous system and autoimmune conditions across Japan.

The company also holds a licensing agreement with NKMAX Co., Ltd. to further the research and development of its natural killer cell initiatives.